Clinical Trial Results: CD40L Antagonism in Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 trial of a CD40L antagonist in rheumatoid arthritis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CD40L antagonist (CD40 ligand antagonist)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2026-07-20